- Home
- UVE vs PVLA Comparison
UVE vs PVLA Comparison
Compare UVE & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UVE
- PVLA
- Stock Information
- Founded
- UVE 1990
- PVLA 2015
- Country
- UVE United States
- PVLA United States
- Employees
- UVE N/A
- PVLA N/A
- Industry
- UVE Property-Casualty Insurers
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- UVE Finance
- PVLA Health Care
- Exchange
- UVE Nasdaq
- PVLA Nasdaq
- Market Cap
- UVE 666.1M
- PVLA 604.2M
- IPO Year
- UVE 1992
- PVLA N/A
- Fundamental
- Price
- UVE $28.86
- PVLA $70.93
- Analyst Decision
- UVE
- PVLA Strong Buy
- Analyst Count
- UVE 0
- PVLA 12
- Target Price
- UVE N/A
- PVLA $68.67
- AVG Volume (30 Days)
- UVE 190.8K
- PVLA 203.2K
- Earning Date
- UVE 10-23-2025
- PVLA 11-15-2025
- Dividend Yield
- UVE 2.69%
- PVLA N/A
- EPS Growth
- UVE N/A
- PVLA N/A
- EPS
- UVE 2.28
- PVLA N/A
- Revenue
- UVE $1,567,371,000.00
- PVLA N/A
- Revenue This Year
- UVE $1.87
- PVLA N/A
- Revenue Next Year
- UVE N/A
- PVLA N/A
- P/E Ratio
- UVE $12.54
- PVLA N/A
- Revenue Growth
- UVE 5.64
- PVLA N/A
- 52 Week Low
- UVE $18.72
- PVLA $11.17
- 52 Week High
- UVE $30.48
- PVLA $77.77
- Technical
- Relative Strength Index (RSI)
- UVE 61.05
- PVLA 55.39
- Support Level
- UVE $27.89
- PVLA $70.98
- Resistance Level
- UVE $30.02
- PVLA $77.77
- Average True Range (ATR)
- UVE 0.80
- PVLA 4.86
- MACD
- UVE -0.15
- PVLA -0.50
- Stochastic Oscillator
- UVE 47.59
- PVLA 42.40
About UVE UNIVERSAL INSURANCE HOLDINGS INC
Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums, earned net interest and dividend income from the investment portfolio, the collection of reinsurance recoverable and financing fees. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.